Mannkind Corp (MNKD)

Oct 22, 2026

Price to earnings forward of MannKind Corporation – SWB:NNFN - TradingView

Oct 22, 2026

Oct 20, 2026

MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth - Yahoo Finance

Oct 20, 2026

Oct 20, 2026

MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth - TradingView

Oct 20, 2026

Oct 20, 2026

MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth - TradingView

Oct 20, 2026

Oct 20, 2026

Chardan starts coverage of MannKind stock with a USD 10.00 target - AD HOC NEWS

Oct 20, 2026

Oct 20, 2026

MNKD Reiterated by Cantor Fitzgerald -- Price Target Maintained at $8.00 - GuruFocus

Oct 20, 2026

Oct 19, 2026

Learn Why The Bull Case For MannKind Stock Could Change Following Outpatient Diuretic Data - Yahoo Finance

Oct 19, 2026

Oct 19, 2026

MNKD: IPF pipeline advances as ReadyFlow and TYVASO DPI support growth and diversification - TradingView

Oct 19, 2026

Oct 19, 2026

Chardan initiates MannKind stock coverage with buy rating on pipeline - Investing.com

Oct 19, 2026

Oct 19, 2026

This MannKind Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga

Oct 19, 2026

Oct 19, 2026

MNKD Initiates Coverage On Chardan Capital -- Price Target Annou - GuruFocus

Oct 19, 2026

Oct 15, 2026

Does MannKind (MNKD) Have a Differentiated Cardiorenal Strategy or Just Incremental Delivery Innovation? - Yahoo Finance

Oct 15, 2026

Oct 15, 2026

MannKind stock rises 4.54 percent on Nasdaq at EUR 2.81 - ad-hoc-news.de

Oct 15, 2026

Oct 14, 2026

MannKind CEO to join panel on chronic respirato... - Pluang

Oct 14, 2026

Oct 14, 2026

MannKind to Participate in the Chardan Healthcare Conference - GlobeNewswire Inc.

Oct 14, 2026

Oct 14, 2026

MannKind to Participate in the Chardan Healthcare Conference - GlobeNewswire

Oct 14, 2026

Oct 14, 2026

MannKind to Participate in the Chardan Healthcare Conference - GlobeNewswire

Oct 14, 2026

Oct 09, 2026

A heart-failure injector delivers a full dose in under 10 seconds. Urine output was similar to treatment into a vein. - Stock Titan

Oct 09, 2026

Oct 09, 2026

New data supports Furoscix ReadyFlow autoinject... - Pluang

Oct 09, 2026

Oct 09, 2026

MannKind Presents New Data Showing Furoscix ReadyFlow Delivers IV-Equivalent Diuresis Across Injection Sites at HFSA 2026 - Quiver Quantitative

Oct 09, 2026

Oct 09, 2026

MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD) - GlobeNewswire Inc.

Oct 09, 2026

Oct 07, 2026

MNKD Maintains Buy Rating -- Price Target Lowered to $5.00 by Truist Securities - GuruFocus

Oct 07, 2026

Oct 05, 2026

MannKind stock weighs 43 percent revenue growth against losses - AD HOC NEWS

Oct 05, 2026

Sep 30, 2026

Delaware Court Ruling Boosts MannKind (MNKD) Outlook Amid Liquid - GuruFocus

Sep 30, 2026

Sep 30, 2026

MNKD Stock Draws Trader Focus On Rose Pharma GLP-1 Deal - StocksToTrade

Sep 30, 2026

Sep 30, 2026

MNKD Stock In Focus After Rose Pharma GLP-1 Licensing Deal - timothysykes.com

Sep 30, 2026

Sep 30, 2026

MNKD Stock In Focus After Rose Pharma GLP-1 Licensing Deal - timothysykes.com

Sep 30, 2026

Sep 29, 2026

Steven Binder sells $128,477 of MannKind (MNKD) stock By Investing.com - Investing.com South Africa

Sep 29, 2026

Sep 28, 2026

Director Steven Binder Sells 39,051 Shares of MannKind Corp (MNK - GuruFocus

Sep 28, 2026

Sep 28, 2026

Steven Binder sells $128,477 of MannKind (MNKD) stock By Investing.com - Investing.com Nigeria

Sep 28, 2026

Sep 28, 2026

Form 4 MannKind Corp For: 28 September By Investing.com - Investing.com Nigeria

Sep 28, 2026

Sep 28, 2026

Steven Binder sells $128,477 of MannKind (MNKD) stock - Investing.com

Sep 28, 2026

Sep 28, 2026

Steven Binder sells $128,477 of MannKind (MNKD) stock By Investing.com - Investing.com Canada

Sep 28, 2026

Sep 25, 2026

Form 144 MannKind Corporation For: 25 September - Investing.com India

Sep 25, 2026

Sep 25, 2026

Form 144 MannKind Corporation For: 25 September By Investing.com - Investing.com Canada

Sep 25, 2026

Sep 25, 2026

Shares valued at $128,478 are proposed for sale by MannKind (MNKD) director Steven Binder. - Stock Titan

Sep 25, 2026

Sep 23, 2026

Danbury Company Reports Positive Results In Lung Disease Drug Trial - Patch

Sep 23, 2026

Sep 23, 2026

MannKind Corporation (MNKD) Options ChainYahoo Finance - Yahoo! Finance Canada

Sep 23, 2026

Sep 22, 2026

MannKind Corporation (MNKD) Stock Analysis: Exploring a 127.68% Potential Upside in the Biotech Space - DirectorsTalk Interviews

Sep 22, 2026

Sep 19, 2026

MNKD Stock Rises 8% On Furoscix ReadyFlow Approval And $50M Funding Boost - Stocktwits

Sep 19, 2026

Sep 18, 2026

Mannkind Stock Price Forecast. Should You Buy MNKD? - StockInvest.us

Sep 18, 2026

Sep 17, 2026

MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum - TradingView

Sep 17, 2026

Sep 15, 2026

MannKind (MNKD) Bets On Inhaled Weight Loss Amid Widening Losses - Yahoo Finance

Sep 15, 2026

Sep 12, 2026

Cantor Fitzgerald reiterates Overweight on MannKind stock at $8 By Investing.com - Investing.com Nigeria

Sep 12, 2026

Sep 11, 2026

Cantor Fitzgerald reiterates Overweight rating on MannKind stock By Investing.com - Investing.com Nigeria

Sep 11, 2026

Sep 11, 2026

Cantor Fitzgerald reiterates Overweight on MannKind stock at $8 By Investing.com - Investing.com South Africa

Sep 11, 2026

Sep 11, 2026

Cantor Fitzgerald reiterates Overweight rating on MannKind stock By Investing.com - Investing.com Canada

Sep 11, 2026

Sep 11, 2026

Cantor Fitzgerald reiterates Overweight on MannKind stock at $8 By Investing.com - Investing.com India

Sep 11, 2026

Sep 11, 2026

Cantor Fitzgerald reiterates Overweight rating on MannKind stock - investing.com

Sep 11, 2026

Sep 11, 2026

MNKD Reiterates by Cantor Fitzgerald -- Price Target Maintained at $6.50 - GuruFocus

Sep 11, 2026